Payment overview · 2025
General Payments
$377.33
13 reported records · 9 companies
Healthcare provider profile · identity verified
Sudheer Gurram, MD
Allopathic & Osteopathic Physicians|Internal Medicine · EVANSVILLE, IN · NPI 1336201243
Verified facts
What the public records show
CMS Open Payments records show Sudheer Gurram, MD received $377.33 in general payments during 2025 across 13 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 34.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $128.39 | 34.0% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $83.33 | 22.1% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.50 | 9.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $35.96 | 9.5% | 1 | 2025 |
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $27.22 | 7.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.70 | 5.0% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $18.11 | 4.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.67 | 3.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.45 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $377.33 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $128.39 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $83.33 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $35.96 | 1 | 2025 |
Source payment records
|
|||||
| NEMLUVIO Normalized: nemluvio |
Drug | Galderma Laboratories, L.P. | $27.22 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $18.11 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 67 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
67 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 215 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 200 | 57 |
| Lisinopril | Lisinopril | 197 | 49 |
| Montelukast Sodium | Montelukast Sodium | 196 | 54 |
| Atorvastatin Calcium | Atorvastatin Calcium | 191 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 157 | 36 |
| Alprazolam | Alprazolam | 151 | 25 |
| Losartan Potassium | Losartan Potassium | 145 | 40 |
| Omeprazole | Omeprazole | 140 | 37 |
| Simvastatin | Simvastatin | 122 | 33 |
| Metformin Hcl | Metformin Hcl | 117 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 115 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 110 | 33 |
| Gabapentin | Gabapentin | 105 | 27 |
| Furosemide | Furosemide | 104 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 37 |
| Lorazepam | Lorazepam | 102 | 22 |
| Clonazepam | Clonazepam | 95 | 13 |
| Allopurinol | Allopurinol | 94 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 88 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 82 | 22 |
| Metformin Hcl Er | Metformin Hcl | 79 | 22 |
| Carvedilol | Carvedilol | 78 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 74 | 23 |
| Tramadol Hcl | Tramadol Hcl | 71 | 21 |
| Famotidine | Famotidine | 70 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 69 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 68 | 16 |
| Eliquis | Apixaban | 67 | 16 |
| Potassium Chloride | Potassium Chloride | 67 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 13 |
| Meloxicam | Meloxicam | 65 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 17 |
| Atenolol | Atenolol | 61 | 12 |
| Terbinafine Hcl | Terbinafine Hcl | 58 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 55 | 14 |
| Trazodone Hcl | Trazodone Hcl | 54 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | suppressed |
| Prednisone | Prednisone | 52 | 13 |
| Promethazine Hcl | Promethazine Hcl | 52 | 11 |
| Diazepam | Diazepam | 51 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 14 |
| Pregabalin | Pregabalin | 49 | 11 |
| Sertraline Hcl | Sertraline Hcl | 48 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 45 | suppressed |
| Jardiance | Empagliflozin | 44 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | suppressed |
| Glipizide Er | Glipizide | 40 | 12 |
| Benazepril Hcl | Benazepril Hcl | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 15 |
| Buspirone Hcl | Buspirone Hcl | 38 | 13 |
| Clonidine Hcl | Clonidine Hcl | 38 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Baclofen | Baclofen | 36 | 17 |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Clonidine | Clonidine | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 23 |
| Glipizide | Glipizide | 33 | suppressed |
| Methylprednisolone | Methylprednisolone | 33 | 28 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 12 |
| Ozempic | Semaglutide | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 28 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 12 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 13 |
| Topiramate | Topiramate | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 11 |
| Estradiol | Estradiol | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 12 |
| Cephalexin | Cephalexin | 19 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 17 |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Xtampza Er | Oxycodone Myristate | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Fluvastatin Sodium | Fluvastatin Sodium | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Perphenazine-Amitriptyline | Perphenazine/Amitriptyline Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $377.33 · 13 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, Cologuard Collection Kit, DUPIXENT, ELIQUIS, EVENITY, Kerendia, LYBALVI, NEMLUVIO, NURTEC ODT, QULIPTA, UBRELVY, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error